Bram Verstockt, ECCO-IBD 2022: Upadacitinib Transcriptional Changes in Ulcerative Colitis: Analysis of the U-ACHIEVE Study
It was a pleasure to talk with Dr. Bram Verstockt (KU Leuven, Leuven, Belgium) around his analysis of the U-ACHIEVE study, investigating transcriptional changes caused by upadacitinib in UC.
The abstract ‘Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE’ (Presentation no. OP30) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- What has the U-ACHIEVE study taught us about the efficacy and safety of upadacitinib in patients with moderately to severely active Ulcerative Colitis (UC)? (0:16)
- What was the rationale for the current analysis of U-ACHIEVE biopsy samples? (0:54)
- Could you tell us a little about the analyses that were undertaken and their findings? (1:29)
- What are the clinical implications of these findings? (3:00)
- Where do you see JAK inhibitors fitting into future treatment paradigms for UC? (3:59)
Disclosures: Bram Verstockt has received research support from Pfizer; speaker fees from Abbvie, Biogen, Bristol Myers Squibb, Chiesi, Falk, Ferring, Galapagos, Janssen, MondayNightIBD, MSD, Pfizer, R-Biopharm, Takeda and Truvion; and consultancy fees from Alimentiv, Applied Strategic, Atheneum, Bristol Myers Squibb, Galapagos, Guidepont, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!